Analysis on survival and prognostic factors in patients with resectable pancreatic adenocarcinoma

2017 ◽  
Vol 37 (4) ◽  
pp. 612-620 ◽  
Author(s):  
Rong Lin ◽  
Chao-qun Han ◽  
Wei-jun Wang ◽  
Jun Liu ◽  
Wei Qian ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Pancreatic Adenocarcinoma

scholarly journals Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?

2021 ◽  
Vol 11 (4) ◽  
pp. 245
Author(s):  
Laura Cortesi ◽  
Claudia Piombino ◽  
Angela Toss
Keyword(s):  
Prognostic Factors ◽  
Homologous Recombination ◽  
Pancreatic Adenocarcinoma ◽  
Objective Response ◽  
Metastatic Breast ◽  
Germline Mutations ◽  
Response To Treatment ◽  
Homologous Recombination Repair ◽  
Dna Breaks ◽  
Recombination Repair

The homologous recombination repair (HRR) pathway repairs double-strand DNA breaks, mostly by BRCA1 and BRCA2, although other proteins such as ATM, CHEK2, and PALB2 are also involved. BRCA1/2 germline mutations are targeted by PARP inhibitors. The aim of this commentary is to explore whether germline mutations in HRR-related genes other than BRCA1/2 have to be considered as prognostic factors or predictive to therapies by discussing the results of two articles published in December 2020. The TBCRC 048 trial published by Tung et al. showed an impressive objective response rate to olaparib in metastatic breast cancer patients with germline PALB2 mutation compared to germline ATM and CHEK2 mutation carriers. Additionally, Yadav et al. observed a significantly longer overall survival in pancreatic adenocarcinoma patients with germline HRR mutations compared to non-carriers. In our opinion, assuming that PALB2 is a high-penetrant gene with a key role in the HRR system, PALB2 mutations are predictive factors for response to treatment. Moreover, germline mutations in the ATM gene provide a better outcome in pancreatic adenocarcinoma, being more often associated to wild-type KRAS. In conclusion, sequencing of HRR-related genes other than BRCA1/2 should be routinely offered as part of a biological characterization of pancreatic and breast cancers.

Prognostic Factors in Nonresectable Pancreatic Adenocarcinoma: A Rationale to Design Therapeutic Trials

1999 ◽  
Vol 94 (5) ◽  
pp. 1271-1278 ◽  
Author(s):  
Joaquín Cubiella ◽  
Antoni Castells ◽  
Constantino Fondevila ◽  
Miquel Sans ◽  
Luís Sabater ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Pancreatic Adenocarcinoma ◽  
Therapeutic Trials

scholarly journals Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation

Cancer ◽  
2006 ◽  
Vol 107 (11) ◽  
pp. 2589-2596 ◽  
Author(s):  
Sunil Krishnan ◽  
Vishal Rana ◽  
Nora A. Janjan ◽  
James L. Abbruzzese ◽  
Morris S. Gould ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Pancreatic Adenocarcinoma ◽  
Locally Advanced ◽  
Locally Advanced Pancreatic Adenocarcinoma ◽  
Advanced Pancreatic Adenocarcinoma

Prognostic Factors in Patients With Advanced Pancreatic Adenocarcinoma Treated With Intra-Arterial Chemotherapy

Pancreas ◽  
2008 ◽  
Vol 36 (1) ◽  
pp. 56-60 ◽  
Author(s):  
Andrea Mambrini ◽  
Claudio Bassi ◽  
Paola Pacetti ◽  
Tito Torri ◽  
Calogero Iacono ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Pancreatic Adenocarcinoma ◽  
Advanced Pancreatic Adenocarcinoma

scholarly journals Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.

2020 ◽  
Author(s):  
In-Ho Kim ◽  
Moon Hyung Choi ◽  
In Seok Lee ◽  
Tae Ho Hong ◽  
Myung Ah Lee
Keyword(s):  
Skeletal Muscle ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Pancreatic Adenocarcinoma ◽  
Cox Regression ◽  
First Line ◽  
Poor Overall Survival ◽  
Skeletal Muscle Index ◽  
Muscle Density ◽  
Metastatic Pancreatic Adenocarcinoma

Abstract Background To investigate the clinical impact of sarcopenia and skeletal muscle density among patients with metastatic pancreatic adenocarcinoma who underwent palliative first line gemcitabine-based chemotherapy. Methods A total of 330 patients with metastatic pancreatic adenocarcinoma who were treated with palliative first line gemcitabine-based chemotherapy between January 2010 and March 2017 were included in this study. Sarcopenia and skeletal muscle density status were identified by L3 vertebra level skeletal muscle index in cm 2 /m 2 and muscle attenuation in Hounsfield units using computed tomography. Results A skeletal muscle index to skeletal muscle density comparison revealed a positive correlation (R 2 = 0.058, P<0.001). Kaplan–Meier analysis showed that low skeletal muscle density was associated with poor overall survival. Multivariate analysis using Cox regression showed that low skeletal muscle index and low skeletal muscle density were poor prognostic factors for overall survival, respectively. Co-presence of low skeletal muscle index and low skeletal muscle density had more powerful prognostic implication for overall survival. Grade 3 or higher toxicity of chemotherapy was more frequently observed in patients with low skeletal muscle index and low skeletal muscle density. Overall survival was not associated with skeletal muscle density status among patients who were chemotherapy responders (complete or partial responses). However, among non-responders (stable or progressive disease), low skeletal muscle density groups had significantly poorer overall survival than did the high skeletal muscle density groups. Conclusions Sarcopenia and skeletal muscle density status can be considered a prognostic factor in patients with metastatic pancreatic adenocarcinoma who receive palliative first line gemcitabine-based chemotherapy. Severe chemotherapy toxicity occurred in the sarcopenia and low skeletal muscle density groups. Our data suggest that comprehensive assessment of skeletal muscle parameters may be more useful prognostic factors.

scholarly journals Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy : a retrospective observational study.

2020 ◽  
Author(s):  
In-Ho Kim ◽  
Moon Hyung Choi ◽  
In Seok Lee ◽  
Tae Ho Hong ◽  
Myung Ah Lee
Keyword(s):  
Skeletal Muscle ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Pancreatic Adenocarcinoma ◽  
Cox Regression ◽  
First Line ◽  
Poor Overall Survival ◽  
Skeletal Muscle Index ◽  
Muscle Density ◽  
Metastatic Pancreatic Adenocarcinoma

Abstract Background: To investigate the clinical impact of sarcopenia and skeletal muscle density among patients with metastatic pancreatic adenocarcinoma who underwent palliative first line gemcitabine-based chemotherapy.Methods: A total of 330 patients with metastatic pancreatic adenocarcinoma who were treated with palliative first line gemcitabine-based chemotherapy between January 2010 and March 2017 were included in this study. Sarcopenia and skeletal muscle density status were identified by L3 vertebra level skeletal muscle index in cm2/m2 and muscle attenuation in Hounsfield units using computed tomography.Results: A skeletal muscle index to skeletal muscle density comparison revealed a positive correlation (R2 = 0.058, P<0.001). Kaplan–Meier analysis showed that the low skeletal muscle density was related to poor overall survival. Multivariate analysis using Cox regression showed that low skeletal muscle index and low skeletal muscle density were poor prognostic factors for overall survival, respectively. Co-presence of low skeletal muscle index and low skeletal muscle density had more powerful prognostic implication for overall survival. Grade 3 or higher toxicity of chemotherapy was more frequently observed in patients who have a low skeletal muscle index and low skeletal muscle density. Overall survival was not related to skeletal muscle density status among patients who were chemotherapy responders (complete or partial responses). However, among non-responders (stable or progressive disease), low skeletal muscle density groups had significantly poorer overall survival in comparison with high skeletal muscle density groups.Conclusions: Sarcopenia and skeletal muscle density status can be considered a prognostic factor in patients with metastatic pancreatic adenocarcinoma who received palliative first line gemcitabine-based chemotherapy. Severe chemotherapy toxicity occurred in the sarcopenia and low skeletal muscle density groups. Our data suggest that a comprehensive assessment of skeletal muscle parameters may be more useful prognostic factors.

Prognostic factors in resected pancreatic adenocarcinoma: Analysis of 5 year Survivors

2001 ◽  
Vol 120 (5) ◽  
pp. A483-A484
Author(s):  
S CLEARY ◽  
R GRYFE ◽  
P GREIG ◽  
L SMITH ◽  
B TAYLOR ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Pancreatic Adenocarcinoma

Prognostic Factors and Adjuvant Chemoradiation Therapy After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma

2009 ◽  
Vol 13 (9) ◽  
pp. 1699-1706 ◽  
Author(s):  
Dong Do You ◽  
Hyung Geun Lee ◽  
Jin Seok Heo ◽  
Seong Ho Choi ◽  
Dong Wook Choi
Keyword(s):  
Prognostic Factors ◽  
Pancreatic Adenocarcinoma ◽  
Chemoradiation Therapy ◽  
Adjuvant Chemoradiation

Tu1939 A Retrospective Single Center Analysis of Survival and Prognostic Factors of Adjuvant Gemcitabine Following Curative-Intended Surgery of Pancreatic Adenocarcinoma

2015 ◽  
Vol 148 (4) ◽  
pp. S-940
Author(s):  
Marlène Nguimpi-Tambou ◽  
Philippe Bachellier ◽  
Vanessa Juif ◽  
Jean-Marie Reimund ◽  
Bernard Duclos
Keyword(s):  
Prognostic Factors ◽  
Pancreatic Adenocarcinoma ◽  
Single Center
Sign in / Sign up

Export Citation Format

Share Document